BioAffinity Advances Noninvasive CyPath Lung Test For Post-Treatment Monitoring
bioAffinity stock trades higher as it advances its CyPath Lung test for post-treatment lung cancer surveillance.
BioAffinity is working on a new test that checks if lung cancer patients are doing okay after treatment, without needing surgery. When companies make progress on new tools that help doctors, investors often feel hopeful about the company's future.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.